Payment overview · 2025
General Payments
$1,582.57
21 reported records · 15 companies
Healthcare provider profile · identity verified
Allan Marvin Ramirez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · LOUISVILLE, KY · NPI 1457389280
Verified facts
What the public records show
CMS Open Payments records show Allan Marvin Ramirez, M.D. received $1,582.57 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cresemba.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Creon by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Cresemba by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
VERTEX PHARMACEUTICALS INCORPORATED reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRIKAFTA as an associated drug or biological on 29 records involving 20 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trikafta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $228.08 | 14.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $179.08 | 11.3% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $163.77 | 10.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $133.24 | 8.4% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $125.99 | 8.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $121.51 | 7.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $119.70 | 7.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.70 | 7.6% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $101.73 | 6.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $95.18 | 6.0% | 1 | 2025 |
| Digestive Care, Inc. | Unresolved — no canonical attribution shown | $69.30 | 4.4% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $43.41 | 2.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $36.53 | 2.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.96 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.39 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,582.57 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $228.08 | 3 | 2025 |
Source payment records
|
|||||
| TOBI PODHALER Normalized: tobi podhaler |
Drug | Viatris Specialty LLC | $179.08 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $163.77 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $133.24 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $121.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $101.73 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $95.18 | 1 | 2025 |
Source payment records
|
|||||
| Pertzye Normalized: pertzye |
Drug | Digestive Care, Inc. | $69.30 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $43.41 | 1 | 2025 |
Source payment records
|
|||||
| ALYFTREK Normalized: alyftrek |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cresemba cresemba |
2025 | Cresemba | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| VERTEX PHARMACEUTICALS INCORPORATED Exact reporting entity; no affiliate inference |
2025 | TRIKAFTA open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 20 recipient NPIs · example record 1213788219 |
Trikafta · 2024 Exact normalized brand match · 1 Part D row |
109 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azithromycin | Azithromycin | 217 | 57 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 203 | 56 |
| Prednisone | Prednisone | 141 | 40 |
| Trikafta | Elexacaftor/Tezacaftor/Ivacaft | 109 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 34 |
| Valganciclovir Hcl | Valganciclovir Hcl | 84 | 23 |
| Carvedilol | Carvedilol | 55 | 18 |
| Tacrolimus | Tacrolimus | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Creon | Lipase/Protease/Amylase | 45 | 11 |
| Eliquis | Apixaban | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 44 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 34 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 33 | 13 |
| Omeprazole | Omeprazole | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | 12 |
| Cresemba | Isavuconazonium Sulfate | 25 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Voriconazole | Voriconazole | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Sirolimus | Sirolimus | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Furosemide | Furosemide | 18 | 11 |
| Cayston | Aztreonam Lysine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fasenra Pen | Benralizumab | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Envarsus Xr | Tacrolimus | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,582.57 · 21 records | AstraZeneca Pharmaceuticals LP | ACTHAR, ALYFTREK, AVYCAZ, Cresemba, EMBLAVEO, FASENRA, Fetroja, Kerendia, OFEV, OPSUMIT, Pertzye, SMARTVEST, TOBI PODHALER, UPTRAVI, WAYRILZ, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cresemba play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error